Controlling myopia progression

Comparison of the Effectiveness of Atropine 0.01% and 0.02% with placebo treatment on Myopia progression Prevention and Probable Side Effects on Children Aged 6-15 Years Old.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180216038747N1

Enrollment

Registered

2018-04-17

Start date

2018-04-04

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia. Myopia

Interventions

Intervention 1: Intervention group 1: Myopic children who will get atropine 0.01% (hand made, in compination with artificial tear in Sina-darou company) one drop in each eye, every night during a year

Eligibility

Sex/Gender

All

Age

6 Years to 15 Years

Inclusion criteria

Inclusion criteria: myopia -0.50 D to -6.00 D Astigmatism <= 0.75 D

Exclusion criteria

Exclusion criteria: myopic children with any ocular diseases such as cataract, glaucoma, uveitis, strabismus, history of trauma, history of any ocular surgery systemic diseases

Design outcomes

Primary

Measure	Time frame
Myopia. Timepoint: before intervention and 12 months after intervention. Method of measurement: auto-keratorefractometer,.;Axial length of the eye. Timepoint: before intervention and 12 months after intervention. Method of measurement: Intra-ocular lens bio-meter,(IOL Master).	—

Secondary

Measure	Time frame
Pupil size. Timepoint: Before intervention and 1 and 12 months after intervention. Method of measurement: Ruler.;Accommodation amplitude. Timepoint: Before intervention and 1 and 12 months after intervention. Method of measurement: Near visual acuity chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Mohaghegh

Shiraz University of Medical Sciences

mohaghegh_sahar@yahoo.com+98 71 3230 2830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026